Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

97.50 -1.18 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Here's How Much $100 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Got $5,000? 2 Unstoppable Stocks to Buy and Hold
These businesses are growing and can be excellent places to make a sizable investment right now. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
Stocks usually go down during recessions, but long-term investors can still come out on top. 
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $1,500 Today
Via Benzinga
Axsome Therapeutics Stock: Bear vs. Bull
2023 will almost certainly see Axsome's top line explode higher. 
Via The Motley Fool
Axsome Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Axsome Therapeutics
Via Benzinga
After Jumping 100%, Is Axsome a Buy Before 2023?
Axsome's revenue story is just getting started. 
Via The Motley Fool
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Where to Invest $1,000 Before the End of 2022
Right now is the perfect time to put your money to work. 
Via The Motley Fool
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way
An economic downturn shouldn't hurt these stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
These Were The Five Best And Worst Performing Mid-Cap Stocks In November 2022
In November, the Dow Jones gained around 7%, the S&P 500 gained 8.4%, and the Nasdaq gained 9.1%. The S&P Mid-Cap 400 performance was in line with major indices. Let’s take a look at the five best and... 
Via Talk Markets
3 Red-Hot Stocks That Could Continue to Beat the Market
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023
These stocks' tailwinds should continue blowing in the new year. 
Via The Motley Fool
3 Surefire Stocks to End 2022 on a Good Note
These stocks should help your portfolio shine now and well into the future. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee of 100% returns for these stocks, but their chances look pretty good. 
Via The Motley Fool
12 Top Stocks to Buy in December
Add this dandy dozen to your stocking this month. 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Exposures Product Safety
FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday
Keybanc lowered Salesforce, Inc. (NYSE: CRM) price target from $210 to $200. . Keybanc analyst Michael Turits maintained an Overweight rating on the stock. Salesforce shares gained 0.5% to $154.45 in... 
Via Benzinga
Tesla, Apple, Anavex, Axsome, Pinduoduo: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% lower on Monday after protests in China against COVID-zero policies led to supply chain concerns. 
Via Benzinga
Dow Tumbles 450 Points; S&P 500 Falls 1.5%
U.S. stocks traded lower toward the end of trading amid protests over COVID-19 restrictions in China. The Dow Jones dropped more than 450 points on Monday. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.